Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Single low-dose un-adjuvanted HBsAg nanoparticle vaccine elicits robust, durable immunity.

Nanomedicine : nanotechnology, biology, and medicine - 1 Oct 2013

Lugade Amit A, Bharali Dhruba J, Pradhan Vandana, Elkin Galina, Mousa Shaker A, Thanavala Yasmin

Abstract excerpt

Chitosan nanoparticles were evaluated as a vaccine delivery system for hepatitis B surface antigen (HBsAg) in the absence of adjuvant. Nano-encapsulated HBsAg (HBsAg chitosan-NP) was endocytosed more rapidly and efficiently by dendritic cells compared to soluble HBsAg. FRET analysis demonstrated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adjuvants, Immunologic
Share to Chitosan
Share to Dose-Response Relationship, Immunologic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B Antibodies

Share to Hepatitis B Vaccines

Share to Immunization

Share to Lymphocyte Count

Share to Nanoparticles

Source

Identifiers

PMID: 23542018
DOI: 10.1016/j.nano.2013.03.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23542018-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Single low-dose un-adjuvanted HBsAg nanoparticle vaccine elicits robust, durable immunity.PMID 23542018Read ↗

PreS1-decorated recombinant adenovirus encoding HBV antigens generates neutralizing humoral and cellular immunitySemantic proximity Read ↗

A multivalent mRNA-LNP therapeutic vaccine with broad cross-genotype immunogenicity elicits clearance of HBV infected hepatocytesSemantic proximity Read ↗

Chitosan nanoparticles as antigen vehicles to induce effective tumor specific T cell responses.Semantic proximity Read ↗

Low immunogenic bio-nanocapsule based on hepatitis B virus escape mutants.Semantic proximity Read ↗

Tunable T cell immunity towards a protein antigen using polymersomes vs. solid-core nanoparticles.Semantic proximity Read ↗

A Single Dose of Anti-HBsAg Antibody-Encoding mRNA-LNPs Suppressed HBsAg Expression: a Potential Cure of Chronic Hepatitis B Virus InfectionSemantic proximity Read ↗

Lipid-polymer hybrid nanoparticles utilize B cells and dendritic cells to elicit distinct antigen-specific CD4 <sup>+</sup> and CD8 <sup>+</sup> T cell responsesSemantic proximity Read ↗

One-step preparation of a self-assembled bioconjugate nanovaccine against BrucellaSemantic proximity Read ↗

Preparation and immunological activity evaluation of an intranasal protein subunit vaccine against ancestral and mutant SARS-CoV-2 with curdlan sulfate/O-linked quaternized chitosan nanoparticles as carrier and adjuvant.Semantic proximity Read ↗

Enhanced presentation of MHC class Ia, Ib and class II-restricted peptides encapsulated in biodegradable nanoparticles: a promising strategy for tumor immunotherapy.Semantic proximity Read ↗

Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201-restricted T-cell epitopes of Mycobacterium tuberculosisSemantic proximity Read ↗

Production and efficacy of a dendritic cell-based therapeutic vaccine for murine chronic hepatitis B virus carrierer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.